JoVE Logo

Sign In

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

10.0K Views

09:44 min

January 29th, 2019

DOI :

10.3791/59041-v

January 29th, 2019


Explore More Videos

Pretargeted Radioimmunotherapy

Chapters in this video

0:04

Title

0:41

The Preparation of huA33-TCO

3:54

177Lu Radiolabeling of Tz-PEG7-DOTA

5:10

In vivo Studies

7:08

Results: Longitudinal Therapy Study of Mice Bearing Subcutaneous SW1222 Tumors

9:00

Conclusion

Related Videos

article

09:29

The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies

17.1K Views

article

10:54

Preparation and Evaluation of 99mTc-labeled Tridentate Chelates for Pre-targeting Using Bioorthogonal Chemistry

8.1K Views

article

10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

8.7K Views

article

09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

3.3K Views

article

07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

2.7K Views

article

08:47

Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates

9.3K Views

article

11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

7.6K Views

article

05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

6.0K Views

article

07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis

6.9K Views

article

09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

357 Views

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved